ALMIRALL, S.A.
AddressRONDA DEL GENERAL MITRE 151, 08002 BARCELONA 
Listed Capital20,754,134.40 Euros



ALMIRALL
ISINES0157097017 TickerALM Nominal0.12 MarketContinuous Market Admitted Capital20,754,134.40 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
16/04/2014Close10.800010.8300-0.2810.800010.960010.600010.8063643,5356,953,204.61

Last pay
TypeDateConcept
Dividend17/05/2013Annual 2013

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
17/05/2013 - 31/05/20131 x 68Bonus


 2014
until 16/04
2013201220112010
Capitalisation
(thousands of euros)
1,867,8722,047,7411,270,395881,9841,132,793
Shares
(x 1,000)
172,951172,951170,523166,099166,099
Period Last Price
(euros)
10.800011.84007.45005.31006.8200
Period High Price
(euros)
13.030012.10007.79009.050010.2100
Period Low Price
(euros)
10.60007.42005.06004.58006.0000
Volume
(thousands of shares)
48,76160,94142,95950,91671,345
Turnover
(thousands of euros)
582,953601,822267,924345,014568,401

Profile

Almirall is a pharmaceutical company committed to health with a strategy focussed on innovation and international growth. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing. Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), gastrointestinal disorders, psoriasis and other dermatological conditions.

Founded in 1943 in Barcelona (Spain), it started its industrial and commercial operations in 1944. In the sixties it began its research and development activities.   Almirall has evolved to become an outstanding pharmaceutical company in the current European arena; one of its major milestones was to become a listed company in June 2007.

Almirall is one of the leading companies in pharmaceutical development of inhaler products. It has 3 centres and 2 R&D units, 5 production centres and a global workforce of around 2,850 people, of whom over 500 are devoted to R&D.

Almirall’s strategic priorities are to promote research and development, maintain its leadership position in the Spanish market and continue to expand internationally.

Almirall’s medicines are present in more than 70 countries across the 5 continents. It has a direct presence in Europe, Mexico and Canada through 13 affiliates. 

Source: Issuing company.
17/04/2014 00:13:06

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © Bolsas y Mercados Españoles 2014